Treatment of Poison Ivy Dermatitis
Introduction to Topical Corticosteroids
- The American Academy of Dermatology supports the use of high potency topical corticosteroids for severe inflammatory skin conditions, noting their usefulness in treating severe disease and flares with minimal side effects in short-term use 1
First-Line Therapy
- High potency topical corticosteroids, such as clobetasol propionate 0.05% or betamethasone dipropionate 0.05%, are recommended for treating severe poison ivy dermatitis to effectively reduce inflammation and pruritus, and should be applied twice daily to affected areas for up to 2 weeks 1, 2
Systemic Corticosteroids for Extensive Disease
- For extensive poison ivy disease (>30% BSA), consider oral prednisone 0.5-1 mg/kg/day, most effective when started within 48 hours of rash onset, with the American Academy of Dermatology and the American College of Dermatology recommending their use in such cases 1, 2, 3
- A longer course (15 days with taper) of oral prednisone may reduce the need for additional medications compared to a short 5-day course 3
Application Considerations
- Use lower potency steroids (Class V/VI) such as hydrocortisone 2.5% for face and intertriginous areas, and limit application to 7 days in these sensitive areas to prevent skin atrophy, as recommended by the Journal for ImmunoTherapy of Cancer 4
- The use of high potency topical corticosteroids should not exceed 50 mL/week due to the risk of HPA axis suppression, and should not be used longer than 2 consecutive weeks, with the American Academy of Dermatology providing guidelines for their safe use 1
Symptomatic Relief
- For mild symptoms, immediate washing with soap and water, cool compresses, and oatmeal baths can provide symptomatic relief, as these measures can remove up to 100% of urushiol if done immediately, as recommended by the American Heart Association 2
- Oral antihistamines, such as cetirizine/loratadine 10 mg daily or hydroxyzine 10-25 mg four times daily, can be used for pruritus, although they have limited efficacy and should not be relied upon as the primary treatment, as suggested by the Journal for ImmunoTherapy of Cancer and the American College of Allergy, Asthma, and Immunology 4, 2
Intralesional Corticosteroid Injections
- The British Journal of Dermatology recommends triamcinolone acetonide 5-10 mg/mL as the preferred agent for intralesional corticosteroid injections, with hydrocortisone acetate 25 mg/mL as an alternative, administered just beneath the dermis in the upper subcutis, with 0.05-0.1 mL per injection, treating approximately a 0.5 cm diameter area 5
- Multiple injections may be given to cover the affected area, limited primarily by patient discomfort, and a needleless device (e.g., Dermajet) can be used to administer the medication, with effects typically lasting about 9 months, and up to 62% of patients achieving full resolution with monthly injections of triamcinolone acetonide 5
- Skin atrophy at the injection site is a consistent side effect, particularly with triamcinolone, according to the British Journal of Dermatology 6
- Pain during injection is common and may limit the number of injections that can be administered, as reported in the British Journal of Dermatology 5
Monitoring and Follow-up
- The response to intralesional corticosteroid injections should be evaluated within 1-2 weeks after injection, with consideration for repeat injections for persistent areas 5
- Topical steroid treatment should not be continued beyond 2 weeks without medical supervision to avoid skin atrophy, as recommended by the American Academy of Dermatology 7
- The American Academy of Dermatology and other authorities recommend a comprehensive approach to treatment, including topical and systemic corticosteroids, as well as symptomatic relief measures, with a strength of evidence supporting their effectiveness in reducing symptom duration and severity 1, 2